Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Sensei Biotherapeutics Inc (SNSE)

Sensei Biotherapeutics Inc (SNSE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 41,576
  • Shares Outstanding, K 1,340
  • Annual Sales, $ 0 K
  • Annual Income, $ -30,160 K
  • EBIT $ -25 M
  • EBITDA $ -23 M
  • 60-Month Beta -0.10
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.36

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year $-5.40
  • Growth Rate Est. (year over year) +18,600.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
22.98 +34.99%
on 03/31/26
36.07 -14.01%
on 04/02/26
+1.21 (+4.06%)
since 03/02/26
3-Month
8.37 +270.61%
on 02/05/26
36.76 -15.61%
on 02/25/26
+21.38 (+221.62%)
since 01/02/26
52-Week
5.20 +496.54%
on 04/07/25
36.76 -15.61%
on 02/25/26
+23.70 (+323.77%)
since 04/02/25

Most Recent Stories

More News
Sensei Biotherapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update

Faeth acquisition adds PIKTOR, an all-oral combination product candidate targeting multiple nodes of the PI3K/AKT/mTOR pathway $200 million private placement supports...

SNSE : 31.02 (-10.84%)
Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced that, effective on March 11, 2026, Sensei’s Board of Directors granted a new employee an option to purchase 166,435 shares of the Company’s...

SNSE : 31.02 (-10.84%)
Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced that, effective on February 19, 2026, Sensei’s Board of Directors granted 17 new employees, in the aggregate, options to purchase 2,319,893...

SNSE : 31.02 (-10.84%)
Sensei Biotherapeutics Announces Acquisition of Faeth Therapeutics and $200 Million Concurrent Private Placement

Acquisition of Faeth and concurrent $200 million private investment positions the combined company to advance its pipeline across key clinical milestones in endometrial and breast cancer ...

SNSE : 31.02 (-10.84%)
Sensei Biotherapeutics Reports Third Quarter 2025 Financial Results

BOSTON, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics...

SNSE : 31.02 (-10.84%)
Sensei Biotherapeutics Announces Initiation of Strategic Review to Maximize Shareholder Value

BOSTON, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical-stage biotechnology company focused on the discovery and development of next-generation therapeutics...

SNSE : 31.02 (-10.84%)
Sensei Biotherapeutics Reports New Clinical Results Highlighting Durable Progression Free Survival Data for Solnerstotug in PD-(L)1 Resistant Tumors at the ESMO Congress 2025

6-month progression-free survival (PFS) of 50% in the higher 15 mg/kg dose cohort compares favorably to historical PD-(L)1 refractory settings – All clinical responses, including a complete response,...

SNSE : 31.02 (-10.84%)
Sensei Biotherapeutics to Host Virtual KOL Event to Discuss Full Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors on October 20, 2025

BOSTON, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics...

SNSE : 31.02 (-10.84%)
Sensei Biotherapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

BOSTON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics...

SNSE : 31.02 (-10.84%)
Sensei Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

- Full data for Phase 1/2 dose expansion cohort expected by year-end 2025 - - Cash runway into the second quarter of 2026 - BOSTON, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Sensei...

SNSE : 31.02 (-10.84%)

Business Summary

Sensei Biotherapeutics Inc. is a clinical-stage immunotherapy company. It is focused on the discovery and development of therapeutics for cancer. The company's product pipeline includes SNS-301, SNS-401 and SNS-VISTA. Sensei Biotherapeutics Inc. is based in BOSTON, Md.

See More

Key Turning Points

3rd Resistance Point 40.75
2nd Resistance Point 38.41
1st Resistance Point 34.72
Last Price 31.02
1st Support Level 28.68
2nd Support Level 26.35
3rd Support Level 22.65

See More

52-Week High 36.76
Last Price 31.02
Fibonacci 61.8% 24.70
Fibonacci 50% 20.98
Fibonacci 38.2% 17.26
52-Week Low 5.20

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.